You are here

A low-cost point-of-care diagnostic test for simultaneous HIV-1 and STI

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41NR010753-01
Agency Tracking Number: NR010753
Amount: $237,977.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: PHS2007-2
Timeline
Solicitation Year: 2008
Award Year: 2008
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
INFOSCITEX CORPORATION 303 BEAR HILL RD
WALTHAM, MA 02451
United States
DUNS: 004627316
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 () -
Business Contact
Phone: (781) 890-1338
Email: smattox@infoscitex.com
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): An important approach for HIV/AIDS prevention is to diagnose co-infections that significantly increase the transmission of HIV. In this proposal, we propose to develop a rapid point-of-care (POC) test that simultaneous
ly diagnoses HIV-1 and two sexually transmitted infections (STI's). Syphilis and genital herpes are STI's that enhance HIV transmission; if diagnosed, they can be cured with low-cost and effective treatment. The link between syphilis and HIV transmission i
s well-established, and the effectiveness of suppressing genital herpes to reduce HIV acquisition and transmission are being tested in two phase III trials. The overall goal of this NIAID STTR Advanced Technology project is to test the hypothesis that simu
ltaneous, point-of-care (POC) testing of patients with HIV-1 and STI co-infections can lead to lower incidence of HIV/AIDS. The goal of Phase I is to take the first step of this work, by establishing the technical feasibility of developing a high-performin
g but extremely low-cost POC, multiplexed, diagnostic test for HIV-1 and STI's. We will target the design for two settings of final use: sexually transmitted disease (STD) clinics in underserved U.S. communities, and because of its extreme low cost, in hea
lth clinics in developing countries. The technology behind this STTR proposal is based on our previously developed technologies for detecting protein markers (specifically, anti-HIV-1 antibodies) from human serum. These lab-on-a-chip devices exhibited an u
nprecedented low cost. This work was performed at Harvard University, and the pending patents have been exclusively licensed to Claros Diagnostics, a small-business company co-founded by the scientists in 2004. The specific aims for Phase I of this STTR pr
oject are: 1. To develop a lab-on-a-chip configuration with an appropriate selection of reagents for low-cost and simultaneous detection of anti-HIV-1, anti-treponemal, and anti-herpes simplex virus type-2 (HSV-2) antibodies from human whole blood. 2. To d
etermine the flow conditions and internal standards necessary for accurate and repeatable measurements of these three antibodies in whole blood. An important approach for HIV/AIDS prevention is to diagnose co-infections that significantly increase the tran
smission of HIV. This proposal aims to develop a rapid point-of-care (POC) test that simultaneously diagnoses HIV-1 and two sexually transmitted infections (STI's), syphilis and genital herpes.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government